ACB · Aurora Cannabis Inc.

Current Thesis

Aurora Cannabis's takeover thesis requires improved Curaleaf terms or a competing definitive offer before a weekly close below $3.40 invalidates the case. The development since the September 6 note is a regulatory dispute over issuance: Curaleaf announced an application to the Alberta Securities Commission on 2026-09-14, then repeated its existing consideration in a shareholder letter on 2026-09-15. Neither announcement established improved terms. Regulatory application announcement, shareholder letter announcement.

As an inference, the narrative is maturing — the 2026-09-15 solicitation continued the existing offer while the supplied 2026-09-18 market snapshot showed a US$3.87 close and a 14-day relative strength index (RSI) of 39.1. The case remains a single-company transaction dispute; renewed solicitation does not establish a bidding contest. The unchanged terms and weaker momentum support a low-conviction forecast that improved consideration arrives before the published price condition fails.

Bullish and bearish views on Aurora Cannabis Inc.

The model's bull view on Aurora Cannabis Inc. (ACB), in brief: The board formally contests valuation. Aurora's 2026-09-02 directors' circular unanimously rejected the offer following an independent special committee review. This establishes opposition to the opening terms, without establishing that another bidder exists. Aurora's circular… The bear view: Solicitation has not improved consideration. Both cases follow in full.

Bull Case

• The board formally contests valuation. Aurora's 2026-09-02 directors' circular unanimously rejected the offer following an independent special committee review. This establishes opposition to the opening terms, without establishing that another bidder exists. Aurora's circular announcement.
• The bidder remains publicly engaged. Curaleaf's 2026-09-15 letter repeated its offer and announced a shareholder question-and-answer session for 2026-09-17. Continued engagement supports the existence of a live negotiation opportunity; a withdrawal without a competing definitive offer would eliminate that route. Curaleaf's announcement.

Bear Case

• Solicitation has not improved consideration. Curaleaf's 2026-09-15 announcement still specified 0.3463 Curaleaf shares and US$0.75 cash per Aurora share. A campaign for acceptance is evidence of effort, not evidence that the bidder will increase its terms. Curaleaf's announcement.
• Issuance complicates the transaction dispute. In its 2026-09-14 announcement, Curaleaf alleged approximately 4.9% dilution since its initial approach and requested an expedited hearing to halt Aurora's at-the-market share issuance program. These are the bidder's allegations and requested remedies; the announcement supplies no regulatory finding or hearing date. Curaleaf's application announcement.
• The headline value is historical. The 2026-08-18 offer's implied US$4.00 used Curaleaf's US$9.39 close on 2026-08-10. Its US$5.00 cap limits consideration under the published formula; it is not a promised higher offer. Curaleaf's material change report.

Setup & Price Structure

The supplied adjusted daily-bar snapshot records a US$3.87 close on 2026-09-18, a three-month price increase of 34.8%, and a price 37.9% below the US$6.23 trailing-year high. Those measurements describe a medium-term recovery with subdued recent momentum, given RSI of 39.1. They do not establish a completed base.

The US$3.40 threshold remains the research invalidation published on 2026-09-06; the available snapshot does not independently establish it as repeatedly tested support. No moving-average value, trading-volume series, short-interest figure or ownership breakdown is supplied for 2026-09-18. Crowding cannot be quantified from these observations; the dated issuance dispute is the concrete supply-related evidence.

Catalyst Calendar (next 30 days)

For 2026-09-20 through 2026-10-20, no confirmed company event or regulatory hearing date is established by the cited announcements. Curaleaf's 2026-09-14 request for an expedited hearing remains undated in that release. The shareholder session announced for 2026-09-17 is already past and is not an upcoming catalyst.

• 2026-12-01 — Scheduled offer expiry. The 2026-08-18 offer set expiry at 5:00 p.m. Mountain Time, subject to extension. This later date matters directly: an amendment, competing definitive transaction, completed take-up or lapse would distinguish the possible outcomes of the current dispute. Curaleaf's offer launch.

What Would Change Our Mind

Failure of the published transaction-support threshold ends the price case: a weekly close below $3.40 invalidates the thesis. Independently, withdrawal or lapse of Curaleaf's offer without improved terms or a competing definitive offer would end the proposed transaction-improvement leg. An extension alone would leave that leg unconfirmed.

A filed increase in Curaleaf's consideration or an announced competing definitive offer would establish the thesis outcome, provided it precedes the price invalidation. The 2026-09-15 reaffirmation does not meet that test.

Correlation Notes

The 2026-08-18 exchange ratio creates direct economic exposure to Curaleaf's share price because most consideration consists of its shares. Without a contemporaneous Curaleaf quote, the US$3.87 Aurora close on 2026-09-18 cannot establish a current discount to the offer's value. Published offer terms.

This remains a single-name transaction setup. The supplied 2026-09-18 snapshot contains no paired sector-return series, so it cannot establish correlation with other cannabis equities or attribute Aurora's three-month advance to a group move.